Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Medical Information》 2018-21
Add to Favorite Get Latest Update

Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets

GAN Hong-wan;XIAO De-jun;ZENG Yu;YANG Ping;ZHONG Yu;Department of Dermatology,Ganzhou People's Hospital;Department of Laboratory,Ganzhou People's Hospital;  
Objective To observe the clinical effect of Olopatadine combined with Pidotimod on chronic urticaria and the effect of peripheral blood lymphocyte subsets.Methods 56 patients with chronic urticaria were selected from January to July 2018 in our the department of dermatology of our hospital. According to the random number method, 28 cases in group A and 28 cases in group B were selected.Group A was treated with Olopatadine alone, group B with Olopatadine combined with Pidotimod, and control group with 20 healthy person.After 4 weeks of treatment, the clinical efficacy were compared among A and B, T, B, NK lymphocyte ratio and adverse reactions in three groups were compared.Results The total therapeutic efficiency in group A was 57.14%, which was lower than that in group B 92.85%,the difference was statistically significant(P0.05).Before and after treatment, the levels of CD3~+,CD3~+CD4~+,CD19~+,CD16~+56~+were not significantly changed in group A(P 0.05).CD3~+CD8~+increased and CD3~+CD4~+/CD3~+CD8~+decreased,the difference was statistically significant(P0.05).In group B, there was no significant difference in CD3~+and CD19~+levels before and after treatment(P 0.05),CD3~+CD8~+increased, CD3~+CD4~+,CD3~+CD4~+/CD3~+CD8~+,CD16~+56~+ significantly decreased,the difference was statistically significant(P0.05).After treatment, there was no significant difference in the level of CD19~+between the two groups(P0.05). The levels of CD3~+and CD3~+CD8~+were lower in group B than in group A.The levels of CD3~+CD4~+,CD3~+CD4~+/CD3~+CD8~+,CD16~+56~+were significantly higher than those in group B,the difference was statistically significant(P 0.05).During the course of treatment, 1 patient in group A developed somnolence and 2 in group B, which could be tolerated. Conclusion Olopatadine combined with Pidotimod can effectively treat chronic urticaria, improve the level of lymphocyte subsets in peripheral blood of patients, improve the patients' own immunity, and be safe and effective.
【CateGory Index】: R758.24
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved